• 1
    Reid IR 1998 Glucocorticoid-induced osteoporosis: Assessment and treatment. J Clin Densitometry 1:6573.
  • 2
    Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC, Torgerson DJ 1998 A UK Consensus Group on management of glucocorticoid-induced osteoporosis: An update. J Intern Med 244:271292.
  • 3
    Lane NE, Lukert B 1998 The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 27:465483.
  • 4
    Ishida Y, Heersche JN 1998 Glucocorticoid-induced osteoporosis: Both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res 13:18221826.
  • 5
    Weinstein RS, Manolagas SC 2000 Apoptosis and osteoporosis. Am J Med 108:153164.
  • 6
    Adinoff AD, Hollister JR 1983 Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 309:265268.
  • 7
    Cooper C, Barker DJP, Wickham C 1988 Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. BMJ 297:14431446.
  • 8
    Baltzan M, Suissa S, Bauer DC, Cummings SR 1999 Hip fractures attributable to corticosteroid use. Lancet 353:1327.
  • 9
    LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, Tartarotti D, DellaRocca C 1990 Bone loss in response to long-term glucocorticoid therapy. Bone Miner 8:3951.
  • 10
    Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD 1991 Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 325:544550.
  • 11
    Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van't Hof MA, Lemmens JA 1993 Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 119:963968.
  • 12
    Reid IR, King AR, Alexander CJ, Ibbertson HK 1988 Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:143146.
  • 13
    Reid IR, Heap SW, King AR, Ibbertson HK 1988 Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis. Lancet 2:1144.
  • 14
    Gallacher SJ, Fenner JA, Anderson K, Bryden FM, Banham SW, Logue FC, Cowan RA, Boyle IT 1992 Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: An open pilot study. Thorax 47:932936.
  • 15
    Worth H, Stammen D, Keck E 1994 Therapy of steroid-induced bone loss in adult asthmatics with calcium, vitamin D, and a diphosphonate. Am J Respir Crit Care Med 150:394397.
  • 16
    Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebalt RJ, Papaioannou A, Boratto M, Gordon M, Steele M 1994 Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 21:19221926.
  • 17
    Skingle SJ, Crisp AJ 1994 Increased bone density in patients on steroids with etidronate. Lancet 344:543544.
  • 18
    Mulder H, Struys A 1994 Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheum 33:348350.
  • 19
    Diamond T, McGuigan L, Barbagallo S, Bryant C 1995 Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women. Am J Med 98:459463.
  • 20
    Struys A, Snelder AA, Mulder H 1995 Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 99:235242.
  • 21
    Falcini F, Trapani S, Ermini M, Brandi ML 1996 Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif Tissue Int 58:166169.
  • 22
    Eastell R, Devogelaer JP, Peel NFA, Gill C, Bax DE, Nagant de Deuxchaisnes C, Russell RGG 1996 A double-blind placebo-controlled study to determine the effects of risedronate on bone loss in glucocorticoid-treated rheumatoid arthritis In: PapapoulosSE, LipsP, PolsHAP, JohnstonCC, DelmasPD (eds.) Osteoporosis. Elsevier Science, Amsterdam, The Netherlands, pp. 391393.
  • 23
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie L, Tenenhouse A, Chines AA 1997 Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 337:382387.
  • 24
    Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP 1997 Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial. Calcif Tissue Int 61:266271.
  • 25
    Roux C, Oriente P, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouilles JM, Horlait S, Cortet B 1998 Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. J Clin Endocrinol Metab 83:11281133.
  • 26
    Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG 1998 Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292299.
  • 27
    Saag K, Emkey R, Cividino A, Brown J, Goemaere S, Dumortier T, Daifotis AG, Czachur M 1998 Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids. Bone 23:S182. (abstract 1141)
  • 28
    Reeves HL, Francis RM, Manas DM, Hudson M, Day CP 1998 Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 4:404409.
  • 29
    Sebalt RF, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH 1999 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis. J Rheumatol 26:15451549.
  • 30
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP 2000 Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: A randomized trial. J Bone Miner Res 15:10061013.
  • 31
    Amin S, LaValley MP, Simms RW, Felson DT 1999 The role of vitamin D in corticosteroid-induced osteoporosis: A meta-analytic approach. Arthritis Rheum 42:17401751.
  • 32
    Devogelaer JP, Baudoux C, Nagant de Deuxchaisnes C 1992 Reproducibility of BMD measurements on the Hologic QDR-2000. In: RingEFJ (ed.) Current Research in Osteoporosis and Bone Mineral Measurement. British Institute of Radiology, London, UK, p. 2.
  • 33
    Minne HW, Leidig G, Wuster C, Siromachkostov L, Baldauf G, Bickel R, Sauer P, Lojen M, Ziegler R 1988 A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Miner 3:335349.
  • 34
    Liang KY, Zeger SL 1986 Longitudinal data analysis using generalized linear models. Biometrika 73:1322.
  • 35
    Davis CS 1993 A computer program for regression analysis of repeated measures using generalized estimating equations. Comput Methods Programs Biomed 40:1531.
  • 36
    Devogelaer JP, Huaux JP, Nagant de Deuxchaisnes C, Esselinckx W 1981 L'atteinte hépatique dans la pseudo-polyarthrite rhizomélique. Rhumatologie 33:131133.
  • 37
    Hall GM, Spector TD, Delmas PD 1995 Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Arthritis Rheum 38:902906.
  • 38
    Nielsen HK, Charles P, Mosekilde L 1988 The effect of single oral doses of prednisone on the circadian rhythm of serum osteocalcin in normal subjects. J Clin Endocrinol Metab 67:10251030.
  • 39
    Kotowicz MA, Hall S, Hunder GG, Cedel Sl, Mann KG, Riggs BL 1990 Relationship of glucocorticoid dosage to serum bone GLA-protein concentration in patients with rheumatologic disorders. Arthritis Rheum 33:14871492.
  • 40
    Gram J, Junker P, Nielsen HK, Bollerslev J 1998 Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 23:297302.
  • 41
    Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH 1997 Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298307.
  • 42
    Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C 1998 Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:22902300.
  • 43
    Ravn P, Clemmesen B, Christiansen C 1999 Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 24:237244.
  • 44
    Fitton A, McTavish D 1991 Pamidronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289318.
  • 45
    Adami S, Zamberlan N 1996 Adverse effects of bisphosphonates. Drug Safety 14:158170.
  • 46
    Thiebaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386392.